- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/285 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
Patent holdings for IPC class C07K 14/285
Total number of patents in this class: 133
10-year publication summary
17
|
10
|
15
|
9
|
7
|
8
|
10
|
14
|
6
|
1
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Glaxosmithkline Biologicals S.A. | 1631 |
15 |
Engineered Antigens Inc. | 10 |
6 |
Serimmune Inc. | 19 |
6 |
Research Institute at Nationwide Children's Hospital | 557 |
4 |
Biotechnology Research and Development Corporation | 13 |
3 |
University of Southern California | 2114 |
3 |
Duke University | 3065 |
3 |
Arne Forsgren et AL | 4 |
3 |
CEVA Sante Animale | 689 |
3 |
Merial, Inc. | 220 |
3 |
Boehringer Ingelheim Animal Health USA Inc. | 417 |
3 |
Vaxcyte, Inc. | 49 |
3 |
Vaxxinova US, Inc. | 50 |
3 |
Eidgenossische Technische Hochschule Zurich | 98 |
2 |
Imperial College Innovations Limited | 581 |
2 |
Infectious Disease Research Institute | 45 |
2 |
Limmatech Biologics AG | 19 |
2 |
Nationwide Children's Hospital, Inc. | 77 |
2 |
Regents of the University of Minnesota | 2688 |
2 |
Rutgers, The State University of New Jersey | 1890 |
2 |
Other owners | 61 |